ROXANNE KLENK: Open Payments
NPI 1891192654 · LINWOOD, MI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$822 in 39 payments from 16 companies in 2025. Trend: 2023 $193 · 2024 $467 · 2025 $822
Food & beverage: $822
| Company | Payments | Amount |
|---|---|---|
| Vanda Pharmaceuticals Inc. | 12 | $244 |
| Corcept Therapeutics | 4 | $106 |
| Lilly USA, LLC | 3 | $57 |
| GlaxoSmithKline, LLC. | 3 | $53 |
| Axsome Therapeutics, Inc. | 2 | $51 |
| Dexcom, Inc. | 2 | $43 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $41 |
| Astellas Pharma US Inc | 2 | $41 |
| ABBVIE INC. | 2 | $39 |
| Neurocrine BioSciences, Inc. | 1 | $24 |
Products named: FANAPT, Korlym, MOUNJARO, TRELEGY ELLIPTA, Auvelity, Dexcom G6 Transmitter, CAPLYTA, Veozah.
Industry payments across MI — which companies pay providers there.
